Agoraphobia Market Opportunity Assessment and Industry Expansion Strategies 2023

Posted by vinit sawant on March 18th, 2021

Market Research Future has conducted an exhaustive study on the global Agoraphobia treatment market and concluded that the Agoraphobia diagnosis and treatment market is likely to attain 0 mn by the conclusion of 2023. The Agoraphobia Market size is anticipated to develop at a CAGR of 4.3 % over the forecast period 2017-2023.

Agoraphobia is prevalent in around 1.7% of adults with women having a high propensity to be affected by the ailment. Agoraphobia diagnosis and treatment market is significantly fueled by aspects like expanding incidence of stress, sedentary lifestyles, genetic disposition, growing screening and awareness, substance abuse, lack of affection in relations, worsening health standards in the modern lifestyles, etc.

The situation might be real or imaginary such as traveling a public conveyance, being present in an enclosed space or being surrounded by a crowd. Symptoms and signs of a panic attack in agoraphobia include troubled breathing, increased heart rate, dizziness, and chest pain, the feeling of loss of control, excessive sweating, and fear of dying.

Regional Analysis

The US market represents a major share of the global Agoraphobia treatment sector owing to the outstanding reimbursement set-up, surged outlay on healthcare, and favorable insurance programs. The faster market approval of novel devices and technologies in the US is also a significant driver of the global market for agoraphobia diagnosis and treatment.

Global Agoraphobia market is largely dominated by renowned players such as Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Sandoz Inc., Pfizer inc, Mylan Pharmaceuticals Inc., and Apotex Corp